ML-007C-MA for psychotic disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Mar 2026: Trial registered, NCT07459647
  2. 31 Mar 2026: Trial started, NCT07459647

The trials

NCT07459647: A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

State
Under way
Phase
Phase 2
People
500 planned
Started
31 Mar 2026
Primary completion
Feb 2030
Arms
ML-007C-MA
Results
None posted
  1. 10 Mar 2026: Trial registered
  2. 31 Mar 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.